Chikungunya virus

Material Safety Data Sheet-Infectious Substances Chikungunya Virus. April 23,2001. 

An unresolved problem with the use of TC-83, and presumably with other live-attenuated alpha-virus vaccines, is the phenomenon of vaccine interference, in which prior immunity to heterologous alphaviruses inhibits vaccine virus replication and subsequent immune responses. This occurrence has been observed in horses,169 170 in which preexisting antibodies to EEE and WEE may have interfered with TC-83 vaccination. Interference has also been observed in humans, in whom prior vaccination with Chikungunya virus has reduced the response to TC-83, and vice versa (D.J.McC., unpublished research, 1994). 

Igarashi A, Fukuoka T, Fukai K. Passive immunization of mice with rabbit antisera against Chikungunya virus and its components. Biken J. 1971 14 353-355. 

Outbreaks of chikungunya virus have occurred in Africa, India and Asia. Serosurveys have identified asymptomatic adults with transmissible levels of virus [16U]. 

Igarashi, A., 1978, Isolation of a Singh s Aedes albopictus cell clone sensitive to dengue and chikungunya viruses, J. Gen. Virol. 40 531. 

Agent Index A292 Class Index C25 Chikungunya Type Virus Arthritis in wrist, knee, ankle and small joints of extremities. A rash may develop in 1 to 10 days. May present hemorrhagic symptoms. Recovery may be prolonged. Routes Vector (Mosquitoes) Secondary Hazards Vector Cycle Incubation 3 to 11 days Mortality Rate 0% Reservoir — Direct Person-to-Person Transmission does not occur. 

Chikungunya hemorrhagic fever Alphavirus Virus Probable... 

---